Bayer: new approval for protate cancer in China
(CercleFinance.com) - Bayer has announced that the Chinese National Medical Products Authority (NMPA) has approved Nubeqa (darolutamide), in combination with docetaxel, for the treatment of patients with hormone-sensitive metastatic prostate cancer (mHSPC).
Nubeqa was already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Nubeqa was already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) at high risk of developing metastatic disease.
Copyright (c) 2023 CercleFinance.com. All rights reserved.